162573
Alcohol and drug treatment systems in public health perspective:
Monday, November 5, 2007: 10:45 AM
Thomas Babor, PhD
,
Dept of Community Medicine and Health Care, University of Connecticut, Farmington, CT
Kerstin Stenius, PhD
,
Centre for Social Research on Alcohol and Drugs, Stockholm University, Stockholm, Sweden
Anders Romelsjo, MD, PhD
,
Centre for Social Research on Alcohol and Drugs, Stockholm University, Stockholm, Sweden
This presentation describes a public health systems approach to the study of services for people with substance use disorders. Such an approach is broadly conceived to include not only of specialized services for alcohol and drug dependence, but also of medical care and social welfare services that interact with and complement specialized drug and alcohol services. After describing a conceptual model of the substance abuse service system, we discuss how systems of care may contribute to population health and social welfare by reducing the societal burden of substance use disorders. The article summarizes key systems issues pertaining to mediators and moderators of effective treatment systems. It is suggested that systems concepts and research may help to improve access, efficiency, economy, continuity of care, and effectiveness, thereby improving the population impact of treatment services. Finally, the potential benefits of systems thinking in relation to the management of substance use disorders are described in comparison to individual-level clinical approaches.
Learning Objectives: 1. Describe what is meant by a public health systems approach to addiction services
2. Understand the mediators of the population impact of alcohol and drug treatment services
3. Appreciate the potential contributions of access, efficiency, economy, and continuity of care to treatment effectiveness.
Presenting author's disclosure statement:Any relevant financial relationships? No Any institutionally-contracted trials related to this submission?
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines,
and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed
in my presentation.
|